Harrow, Inc.
NASDAQHarrow, Inc. heads into the final week of September with a peculiar split: options traders are the most bullish they've been all year, while short sellers are quietly adding to an already-heavy position — and borrow availability is snapping tighter. The lending market tells the most urgent story this week. Availability dropped to just 18.3% on September 24, down nearly a quarter…
HROW utilization hits 93.83%, near 52-week high of 96.73%, as short availability drops to just 18.3% of SI.
Harrow, Inc. heads into the final week of September with a peculiar split: options traders are the most bullish they've been all year, while short sellers are quietly adding to an already-heavy position — and borrow…
HROW reports today with a short position that has barely budged since yesterday's preview — and the lending market remains tight enough to make a short squeeze a live risk if the print surprises. Short interest is…
Snapshot as of 30 Sept 2026
HROW enters its August 10 print carrying one of the most crowded short positions in the pharmaceutical universe — and the borrow market has tightened sharply in the past week, adding pressure to both sides of the…
Harrow, Inc. enters the second half of 2026 with a sharp internal contradiction — short sellers are rebuilding positions into a stock that just rallied 21% in a month, while options traders are the least bearish…
Harrow, Inc. heads into the back half of 2026 with a striking split in conviction — the co-founders bought the stock aggressively after a steep earnings selloff, while short sellers have quietly added to already…
HROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced. Harrow reported Q1 results after the close on May 11.…
Harrow, Inc. heads into its Q1 2026 earnings today with a short book that remains stubbornly elevated — and a stock that has pulled back sharply from this year's highs. Short sellers are not backing down. At 17% of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HROW — free to start on ORTEX.
Sign up for free →Open HROW on ORTEX